Form 4 holding
President & COO
Zymeworks Inc.
- Security class
- Common Stock
- Shares / value
- 17,032
- Estimated value
- $191,024
- Report date
- 10 Mar 2023
- Price
- $11.22
- Ownership
- Direct
Mr. Neil Klompas
Insider Reports History
- Reporting-owner location
- Vancouver, British Columbia, Canada
- Latest reporting-owner signature
-
/s/ Eric A Adams, attorney-in-fact for Mr. Neil Klompas
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Mr. Neil Klompas
Form 4 holding
Chief Operating Officer
Zymeworks Inc.
- Security class
- Common Shares
- Shares / value
- 14,801
- Estimated value
- $66,753
- Report date
- 05 Jul 2022
- Price
- $4.51
- Ownership
- Direct
Form 4 holding
President & COO
Zymeworks Inc.
- Security class
- Restricted Stock Unit
- Shares / value
- 2,709
- Estimated value
- $30,383
- Report date
- 10 Mar 2023
- Price
- $11.22
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
President & COO
Zymeworks Inc.
- Security class
- Common Stock
- Shares / value
- 700
- Estimated value
- $7,851
- Report date
- 10 Mar 2023
- Price
- $11.22
- Ownership
- Held by spouse
Form 4 holding
Chief Operating Officer
Zymeworks Inc.
- Security class
- Common Shares
- Shares / value
- 700
- Estimated value
- $3,157
- Report date
- 05 Jul 2022
- Price
- $4.51
- Ownership
- Held by spouse
Form 4 holding
Director
InMed Pharmaceuticals Inc.
- Security class
- Employee Stock Option (Right to Buy)
- Shares / value
- 5,250
- Estimated value
- Report date
- 19 Dec 2025
- Price
- Ownership
- Direct
- Underlying class
- Common shares
- Underlying amount
Insider Reports Filed by Mr. Neil Klompas
4
INM
InMed Pharmaceuticals Inc.
- Report period
- 19 Dec 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 19 Dec 2025, 11:42
- Role
- Director
- Next action
- Open filing details
4
INM
InMed Pharmaceuticals Inc.
- Report period
- 17 Oct 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Oct 2025, 13:58
- Role
- Director
- Next action
- Open filing details
3
INM
InMed Pharmaceuticals Inc.
- Report period
- 09 Oct 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 17 Oct 2025, 20:33
- Role
- Director
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 10 Mar 2023
- Transactions
- 5
- Transaction value
- -$23,298
- Accepted by SEC
- 14 Mar 2023, 17:00
- Role
- President & COO
- Next action
- Open filing details
4
ZYME
Zymeworks Inc.
- Report period
- 05 Jan 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2023, 19:00
- Role
- President & COO
- Next action
- Open filing details
4
Zymeworks Inc.
- Report period
- 05 Jul 2022
- Transactions
- 1
- Transaction value
- +$6,878
- Accepted by SEC
- 05 Jul 2022, 21:00
- Role
- Chief Operating Officer
- Next action
- Open filing details
4
Zymeworks Inc.
- Report period
- 10 Mar 2022
- Transactions
- 6
- Transaction value
- -$20,496
- Accepted by SEC
- 11 Mar 2022, 20:00
- Role
- Chief Operating Officer
- Next action
- Open filing details
4
Zymeworks Inc.
- Report period
- 07 Jan 2022
- Transactions
- 1
- Transaction value
- +$3,861
- Accepted by SEC
- 07 Jan 2022, 20:30
- Role
- Chief Operating Officer & CFO
- Next action
- Open filing details
4
Zymeworks Inc.
- Report period
- 06 Jul 2021
- Transactions
- 1
- Transaction value
- +$8,818
- Accepted by SEC
- 08 Jul 2021, 20:00
- Role
- Chief Financial Officer
- Next action
- Open filing details